Held by 5 specialist biotech funds
High Convergence**Signal Note: Driehaus Initiates PEPG Position** Growth-focused Driehaus's $2.1M entry into PepGen suggests conviction in the biotech's pipeline, likely driven by upcoming clinical catalysts for its lead program PGN378, a subcutaneous FcRn inhibitor targeting myasthenia gravis.
AI analyst context — unlock full analysis
# BVF Partners Initiates PepGen Position BVF's $12.5M entry into PEPG suggests conviction in PepGen's muscle disease pipeline, notably PG101 for myasthenia gravis where Phase 2 data is expected in H2 2024/early 2025. The position size (~2.3% of shares outstanding) aligns with Lampert's concentrated value approach, likely betting on clinical validation of the FcRn antagonist platform at a depressed valuation ahead of near-term readouts. This is a pre-clinical catalyst signal rather than a valuation-driven accumulation.
+ 3more — see how much conviction went in
See the Full Story